Noxopharm 2020 June quarter Appendix 4C & Activities Report
Filed with ASX · · 10 pages · English
Story so far
Earlier from Noxopharm
- Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’
- Data Shows Idronoxil Holds Key to Problem of COLD Cancers
- COVID-19 Trial Program to Commence in Europe
- Pro-rata Non-Renounceable Rights Issue Fully Allocated
- ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
Later from Noxopharm
- Peer-Reviewed Publication Strengthens Case For Veyonda
- Appendix 4E and Audited Financial Statements FY2020
- Veyonda COVID-19 Study Approved For Immediate Start
- First COVID-19 Patient Treated in Veyonda Study
- Noxopharm Loan Terms Amended to Benefit Company
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm